California Stem Cell Report

"Some bad news about a $1.8 million gene therapy echoed across the Atlantic Ocean this week and carries implications for California’s state stem cell agency, which also is engaged in developing so-called “one-and-done” therapies.
" The matter involves bluebird bio of Cambridge, Mass., and its proposed Zynteglo therapy for the rare blood disorder beta thalassemia. The European Union last week refused to go along with bluebird’s price for the treatment -- $1.8 million....

Don't miss important fresh news and information about California's $12 billion stem cell research agency. It is charting a new course with new opportunities and significant changes in direction, including a greater emphasis on the fast-growing gene therapy...

 "Indispensable" is what the Los Angeles Times this morning called this blog, the California Stem Cell Report.
The comment came in a story that was triggered by our coverage of the Orchard-CIRM-UCLA bubble baby clinical trial, which was shoved aside by Orchard Therapeutics for financial reasons. That leaves a bunch of children out in the cold as far as the genetic...

 Don't miss out on news and information on the $12 billion California stem cell agency.
Its activities affect the lives of thousands of people and have the potential to affect the lives of millions of more. Not to mention that it is venturing into new areas of health policy and research....